ERBB2 and triple-negative breast carcinoma: In line with these results, our group recently demonstrated tumor-promoting functions of H2Bub1 in HER2-positive breast cancer (HER2+-BC) [43], colorectal [44], and triple-negative breast cancer (TNBC) [45] by supporting the actin cytoskeleton dynamics, anti-apoptotic signaling, and glycolytic capacity, respectively.